Information  X 
Enter a valid email address

Marshall Edwards (MSH)

  Print      Mail a friend

Tuesday 27 August, 2002

Marshall Edwards

Research Update

Marshall Edwards, Inc.
27 August 2002

                             Marshall Edwards Inc.



Yale researchers reveal phenoxodiol's unique ability to kill ovarian cancer
cells



MARSHALL EDWARDS INC. AND YALE UNIVERSITY MEDICAL SCHOOL TO DEVELOP PHENOXODIOL
FOR OVARIAN CANCER



(WASHINGTON, DC - August 27, 2002) Marshall Edwards Inc. (LSE-AIM: MSH), the
subsidiary of pharmaceutical company, Novogen Limited (Nasdaq: NVGN), has
entered into a services agreement with the Yale University School of Medicine's
Department of Obstetrics and Gynecology.



The association with Yale revolves around the recent discovery in Yale Medical
School laboratories that MEI's anti-cancer drug, phenoxodiol, has a uniquely
strong effect against ovarian cancer cells.



Ovarian cancer is the fifth largest cause of death from cancer in women, and the
American Cancer Society estimates that over 23,000 women will develop ovarian
cancer in the US each year.  The treatment options and prognosis for women with
late-stage ovarian cancer remain poor.



In a search for an effective drug to treat ovarian cancer, the research team at
Yale University Medical School, headed by Gil Mor MD PhD, has been screening new
anti-cancer drugs for their ability to kill ovarian cancer cells, and in
particular, to switch off a mechanism on which ovarian cancer cells depend for
survival.



Dr Mor's team has reported that phenoxodiol is a highly effective drug that
kills all ovarian cancer cells and does so by a unique mechanism that causes
ovarian cancer cells to self-destruct.



One of the outcomes of the Yale association will be to arrange a phase II
clinical trial in patients with advanced ovarian cancer at Yale under the
direction of Dr Thomas Rutherford.  This will be a multi-center trial to be
conducted in conjunction with an Australian university hospital.



Under US law, a new drug cannot be marketed until it has been investigated in
clinical trials.  After the results of these trials are submitted in a new drug
application to the FDA, the FDA must approve the drug as safe and effective
before marketing can take place.



MEI, which trades on the Alternative Investment Market of the London Stock
Exchange, is 95 percent owned by Novogen Limited.  MEI was established to
provide a commercial vehicle for Novogen's anti-cancer drug technology, the
first of which is the novel anti-cancer drug phenoxodiol.



Novogen is a pharmaceutical company based in Sydney, Australia with offices in
Stamford, Connecticut. More information on phenoxodiol can be found at
www.novogen.com and www.marshalledwardsinc.com.



Statements herein that are not descriptions of historical facts are
forward-looking and subject to risk and uncertainties. Actual results could
differ materially from those currently anticipated due to a number of factors,
including those set forth in the Company's Securities and Exchange Commission
filings under 'Risk Factors', including risks relating to the early stage of
products under development; uncertainties relating to clinical trials;
dependence on third parties; future capital needs; and risks relating to the
commercialisation, if any, of the Company's proposed products (such as
marketing, safety, regulatory, patent, product liability, supply, competition
and other risks).


FOR FURTHER               US:         DAVID SHEON  TELEPHONE:    +1 202 518 6384

INFORMATION:              AUSTRALIA:  DR GRAHAM KELLY TELEPHONE: +612 8877 6196
                          http://www.marshalledwardsinc.com



DATE                          :            28 AUGUST, 2002





                      This information is provided by RNS
            The company news service from the London Stock Exchange
                                                                                                          

a d v e r t i s e m e n t